Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy

Table 1 Guidelines for the clinical management of hepatocellular carcinoma

	Publishing year	Guidelines	Drafted by	Treatment algorithm for advanced HCC(BCLC C)	Ref.
Asia	2014	JSH-LCSGJ	Japan Society of Hepatology and Liver Cancer Study Group of Japan	HAIC (Vp1-4), Sorafenib (Vp1-3), TACE (Vp1, 2), Resection (Vp1, 2)	[6]
	2014	KLCSG-NCC	Korean Liver Cancer Study Group and National Cancer Center	TACE, Sorafenib	[7]
	2014	HKLC	Hong Kong Liver Cancer	Systemic therapy, Supportive care	[8]
	2017	APASL	Asian-Pacific Association for the Study of the Liver	Systemic therapy (sorafenib and regorafenib), TACE for patients with no extrahepatic metastasis	[9]
	2017	JSH	Japan Society of Hepatology	TACE, Resection, HAIC, Molecular targeted agents	[10]
Europe	2018	EASL	European Association for the Study of the Liver	Sorafenib (sorafenib, lenvatinib, regorafenib, and cabozantinib)	[11]
	2012	ESMO-ESDO	European Society for Medical Oncology and European Society of Digestive Oncology	Sorafenib	[12]
United States	2011	AASLD	American Association for the Study of Liver Disease	Sorafenib	[13]

HAIC: Hepatic arterial infusion chemotherapy; Vp1-4: Portal vein invasion according to JSH-LCSGJ; TACE: Transcatheter arterial chemoembolization; BCLC: Barcelona clinic liver cancer.